CY1125065T1 - Αναστολεις mcl-1 - Google Patents
Αναστολεις mcl-1Info
- Publication number
- CY1125065T1 CY1125065T1 CY20221100208T CY221100208T CY1125065T1 CY 1125065 T1 CY1125065 T1 CY 1125065T1 CY 20221100208 T CY20221100208 T CY 20221100208T CY 221100208 T CY221100208 T CY 221100208T CY 1125065 T1 CY1125065 T1 CY 1125065T1
- Authority
- CY
- Cyprus
- Prior art keywords
- mcl
- inhibitors
- compounds
- methods
- present disclosure
- Prior art date
Links
- 101001056180 Homo sapiens Induced myeloid leukemia cell differentiation protein Mcl-1 Proteins 0.000 title 1
- 102100026539 Induced myeloid leukemia cell differentiation protein Mcl-1 Human genes 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D267/02—Seven-membered rings
- C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D267/16—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with two six-membered rings
- C07D267/20—[b, f]-condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D267/02—Seven-membered rings
- C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C381/00—Compounds containing carbon and sulfur and having functional groups not covered by groups C07C301/00 - C07C337/00
- C07C381/10—Compounds containing sulfur atoms doubly-bound to nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Η παρούσα αποκάλυψη γενικώς αφορά σε ενώσεις και φαρμακευτικές συνθέσεις που μπορεί να χρησιμοποιηθούν σε μεθόδους θεραπείας καρκίνου.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862671306P | 2018-05-14 | 2018-05-14 | |
US201862749918P | 2018-10-24 | 2018-10-24 | |
PCT/US2019/032053 WO2019222112A1 (en) | 2018-05-14 | 2019-05-13 | Mcl-1 inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1125065T1 true CY1125065T1 (el) | 2023-06-09 |
Family
ID=66770559
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20221100208T CY1125065T1 (el) | 2018-05-14 | 2022-03-16 | Αναστολεις mcl-1 |
Country Status (29)
Country | Link |
---|---|
US (4) | US10703733B2 (el) |
EP (2) | EP3793565B1 (el) |
JP (3) | JP6899975B2 (el) |
KR (3) | KR102666717B1 (el) |
CN (2) | CN112118845B (el) |
AU (3) | AU2019269391B2 (el) |
BR (1) | BR112020021648A2 (el) |
CA (1) | CA3099152C (el) |
CL (1) | CL2020002919A1 (el) |
CO (1) | CO2020014009A2 (el) |
CR (1) | CR20200544A (el) |
CY (1) | CY1125065T1 (el) |
DK (1) | DK3793565T3 (el) |
ES (1) | ES2907923T3 (el) |
HR (1) | HRP20220215T1 (el) |
HU (1) | HUE057852T2 (el) |
IL (2) | IL291430B2 (el) |
LT (1) | LT3793565T (el) |
MX (1) | MX2020012137A (el) |
PE (1) | PE20210004A1 (el) |
PH (1) | PH12020551881A1 (el) |
PL (1) | PL3793565T3 (el) |
PT (1) | PT3793565T (el) |
SG (1) | SG11202010964VA (el) |
SI (1) | SI3793565T1 (el) |
TW (2) | TWI719478B (el) |
UA (1) | UA125163C2 (el) |
WO (1) | WO2019222112A1 (el) |
ZA (1) | ZA202007007B (el) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102666717B1 (ko) | 2018-05-14 | 2024-05-20 | 길리애드 사이언시즈, 인코포레이티드 | Mcl-1 억제제 |
EP3997097B1 (en) | 2019-07-09 | 2024-03-20 | Janssen Pharmaceutica NV | Macrocyclic spirocycle derivatives as mcl-1 inhibitors |
AU2020365113A1 (en) | 2019-10-18 | 2022-04-07 | Forty Seven, Inc. | Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia |
KR20220091576A (ko) | 2019-10-31 | 2022-06-30 | 포티 세븐, 인코포레이티드 | 혈액암의 항-cd47 및 항-cd20 기반 치료 |
TWI778443B (zh) | 2019-11-12 | 2022-09-21 | 美商基利科學股份有限公司 | Mcl1抑制劑 |
AU2020391106B2 (en) | 2019-11-26 | 2024-03-21 | Gilead Sciences, Inc. | Processes and intermediates for preparing MCL1 inhibitors |
CN117736207A (zh) | 2019-12-24 | 2024-03-22 | 卡尔那生物科学株式会社 | 二酰基甘油激酶调节化合物 |
US20230212191A1 (en) * | 2020-04-16 | 2023-07-06 | Prelude Therapeutics, Incorporated | Spiro-sulfonimidamide derivatives as inhibitors of myeloid cell leukemia-1 (mcl-1) protein |
KR20230023008A (ko) * | 2020-06-10 | 2023-02-16 | 얀센 파마슈티카 엔.브이. | Mcl-1의 억제제로서의 마크로사이클릭 2-아미노-3-플루오로-부트-3-엔아미드 |
AU2021381769B2 (en) * | 2020-11-19 | 2024-05-30 | Gilead Sciences, Inc. | Processes and intermediates for preparing macrocyclic mcl1 inhibitors |
MX2023007297A (es) | 2020-12-17 | 2023-07-04 | Janssen Pharmaceutica Nv | 3-fluoro-but-3-enamidas ramificadas macrociclicas como inhibidores de mcl-1. |
TW202302145A (zh) | 2021-04-14 | 2023-01-16 | 美商基利科學股份有限公司 | CD47/SIRPα結合及NEDD8活化酶E1調節次單元之共抑制以用於治療癌症 |
BR112023020877A2 (pt) | 2021-04-26 | 2023-12-12 | Janssen Pharmaceutica Nv | 2-aliltetra-hidrofuranos macrocíclicos como inibidores de mcl-1 |
WO2022245671A1 (en) | 2021-05-18 | 2022-11-24 | Gilead Sciences, Inc. | Methods of using flt3l-fc fusion proteins |
CA3222269A1 (en) | 2021-06-11 | 2022-12-15 | Gilead Sciences, Inc. | Combination mcl-1 inhibitors with anti-cancer agents |
AU2022290855A1 (en) | 2021-06-11 | 2023-12-07 | Gilead Sciences, Inc. | Combination mcl-1 inhibitors with anti-body drug conjugates |
WO2022271684A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
AU2022297367A1 (en) | 2021-06-23 | 2023-12-07 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
WO2022271677A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
CA3222439A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
WO2023088894A1 (en) | 2021-11-16 | 2023-05-25 | Janssen Pharmaceutica Nv | Macrocyclic 2-amino-but-3-enamides as inhibitors of mcl-1 |
US20230355796A1 (en) | 2022-03-24 | 2023-11-09 | Gilead Sciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
TW202345901A (zh) | 2022-04-05 | 2023-12-01 | 美商基利科學股份有限公司 | 用於治療結腸直腸癌之組合療法 |
US20230357274A1 (en) * | 2022-05-04 | 2023-11-09 | Gilead Sciences, Inc. | Salts and polymorphs of certain mcl-1 inhibitors |
WO2024064668A1 (en) | 2022-09-21 | 2024-03-28 | Gilead Sciences, Inc. | FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY |
Family Cites Families (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6319494B1 (en) | 1990-12-14 | 2001-11-20 | Cell Genesys, Inc. | Chimeric chains for receptor-associated signal transduction pathways |
IL104570A0 (en) | 1992-03-18 | 1993-05-13 | Yeda Res & Dev | Chimeric genes and cells transformed therewith |
US7446190B2 (en) | 2002-05-28 | 2008-11-04 | Sloan-Kettering Institute For Cancer Research | Nucleic acids encoding chimeric T cell receptors |
WO2005014599A1 (en) | 2003-06-04 | 2005-02-17 | Cellular Genomics, Inc. | Imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of bruton’s tyrosine kinase by such compounds |
US7932260B2 (en) | 2004-05-13 | 2011-04-26 | Icos Corporation | Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta |
US20090142345A1 (en) | 2005-03-15 | 2009-06-04 | Takeda Pharmaceutical Company Limited | Prophylactic/therapeutic agent for cancer |
PL2439273T3 (pl) | 2005-05-09 | 2019-08-30 | Ono Pharmaceutical Co., Ltd. | Ludzkie przeciwciała monoklonalne przeciwko białku programowanej śmierci komórki 1(pd-1) oraz metody leczenia nowotworów z wykorzystaniem przeciwciał anty-pd-1 samodzielnie lub w połączeniu z innymi immunoterapeutykami |
CN104356236B (zh) | 2005-07-01 | 2020-07-03 | E.R.施贵宝&圣斯有限责任公司 | 抗程序性死亡配体1(pd-l1)的人单克隆抗体 |
ES2557930T3 (es) | 2007-03-12 | 2016-01-29 | Ym Biosciences Australia Pty Ltd | Compuestos de fenilaminopirimidina y usos de los mismos |
CN101835490A (zh) | 2007-08-02 | 2010-09-15 | 阿雷斯托生物科学股份有限公司 | Lox和loxl2抑制剂及其应用 |
PL2604693T3 (pl) | 2008-07-21 | 2016-09-30 | Jednołańcuchowe cząsteczki TNFSF | |
WO2010019702A2 (en) | 2008-08-12 | 2010-02-18 | Oncomed Pharmaceuticals, Inc. | Ddr1-binding agents and methods of use thereof |
US8450321B2 (en) | 2008-12-08 | 2013-05-28 | Gilead Connecticut, Inc. | 6-(1H-indazol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo-[1,2-A]pyrazin-8-amine, or a pharmaceutically acceptable salt thereof, as a SYK inhibitor |
TWI625121B (zh) | 2009-07-13 | 2018-06-01 | 基利科學股份有限公司 | 調節細胞凋亡信號之激酶的抑制劑 |
JP6134142B2 (ja) | 2010-02-04 | 2017-05-24 | ギリアド バイオロジクス, インク.Gilead Biologics, Inc. | リシルオキシダーゼ様2(loxl2)に結合する抗体及びその使用方法 |
WO2011146862A1 (en) | 2010-05-21 | 2011-11-24 | Bellicum Pharmaceuticals, Inc. | Methods for inducing selective apoptosis |
ES2739505T3 (es) | 2010-08-27 | 2020-01-31 | Gilead Biologics Inc | Anticuerpos contra la metaloproteinasa 9 de la matriz |
ES2700966T3 (es) | 2010-12-09 | 2019-02-20 | Univ Pennsylvania | Utilización de linfocitos T modificados con receptores de antígeno quiméricos para tratar el cáncer |
TWI567061B (zh) | 2011-07-01 | 2017-01-21 | 吉李德科學股份有限公司 | 用於治療成癮之化合物 |
EP2749572A4 (en) | 2011-08-23 | 2015-04-01 | Chugai Pharmaceutical Co Ltd | NEW ANTI-DDR1 ANTIBODY WITH ANTITUMORACTIVITY |
GB201115529D0 (en) | 2011-09-08 | 2011-10-26 | Imp Innovations Ltd | Antibodies, uses and methods |
WO2013052699A2 (en) | 2011-10-04 | 2013-04-11 | Gilead Calistoga Llc | Novel quinoxaline inhibitors of pi3k |
UY34573A (es) | 2012-01-27 | 2013-06-28 | Gilead Sciences Inc | Inhibidor de la quinasa que regula la señal de la apoptosis |
WO2013116562A1 (en) | 2012-02-03 | 2013-08-08 | Gilead Calistoga Llc | Compositions and methods of treating a disease with (s)-4 amino-6-((1-(5-chloro-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile |
WO2014047624A1 (en) | 2012-09-24 | 2014-03-27 | Gilead Sciences, Inc. | Anti-ddr1 antibodies |
BR112015014585A2 (pt) | 2012-12-21 | 2017-07-11 | Gilead Calistoga Llc | composto, composição farmacêutica, e, método de tratamento de um ser humano |
US9029384B2 (en) | 2012-12-21 | 2015-05-12 | Gilead Calistoga, LLC. | Phosphatidylinositol 3-kinase inhibitors |
TWI527811B (zh) | 2013-05-09 | 2016-04-01 | 吉李德科學股份有限公司 | 作爲溴結構域抑制劑的苯並咪唑衍生物 |
EA028319B1 (ru) | 2013-06-14 | 2017-11-30 | Джилид Калистога Ллс | Ингибиторы фосфатидилинозитол-3-киназы |
KR101810798B1 (ko) | 2013-07-30 | 2017-12-19 | 질레드 코네티컷 인코포레이티드 | Syk 억제제의 다형체 |
US9290505B2 (en) | 2013-12-23 | 2016-03-22 | Gilead Sciences, Inc. | Substituted imidazo[1,2-a]pyrazines as Syk inhibitors |
TWI662037B (zh) | 2013-12-23 | 2019-06-11 | 美商基利科學股份有限公司 | 脾酪胺酸激酶抑制劑 |
CN106456602B (zh) * | 2014-03-27 | 2020-11-24 | 范德比尔特大学 | 取代的吲哚mcl-1抑制剂 |
MY192522A (en) | 2014-04-10 | 2022-08-25 | Seattle Childrens Hospital Dba Seattle Childrens Res Inst | Defined composition gene modified t-cell products |
TWI751102B (zh) | 2014-08-28 | 2022-01-01 | 美商奇諾治療有限公司 | 對cd19具專一性之抗體及嵌合抗原受體 |
JO3474B1 (ar) * | 2014-08-29 | 2020-07-05 | Amgen Inc | مشتقات تيتراهيدرونافثالين التي تثبط بروتين mcl-1 |
ES2727376T3 (es) | 2014-09-26 | 2019-10-15 | Gilead Sciences Inc | Derivados de aminotriazina útiles como compuestos inhibidores de quinasa de unión TANK |
MX2017007138A (es) | 2014-12-03 | 2017-08-28 | Juno Therapeutics Inc | Metodos y composiciones para terapia celular adoptiva. |
WO2016100236A2 (en) | 2014-12-15 | 2016-06-23 | Bellicum Pharmaceuticals, Inc. | Methods for controlled elimination of therapeutic cells |
EP3294732B1 (en) | 2015-05-15 | 2019-09-25 | Gilead Sciences, Inc. | Benzimidazole and imadazopyridine carboximidamide compounds having activity as inhibitors of indoleamine 2,3-dioxygenase |
JP6949728B2 (ja) | 2015-05-29 | 2021-10-13 | ジュノー セラピューティクス インコーポレイテッド | 遺伝子操作された細胞における阻害相互作用を調節するための組成物および方法 |
MX2018003353A (es) | 2015-09-17 | 2018-09-17 | Novartis Ag | Terapias con celulas cart con una eficacia mejorada. |
WO2017147410A1 (en) | 2016-02-25 | 2017-08-31 | Amgen Inc. | Compounds that inhibit mcl-1 protein |
JP6453507B2 (ja) | 2017-03-30 | 2019-01-16 | アムジエン・インコーポレーテツド | Mcl−1タンパク質を阻害する化合物 |
WO2019036575A1 (en) | 2017-08-18 | 2019-02-21 | Amgen Inc. | MCL-1 PROTEIN INHIBITING COMPOUNDS |
EP3676270A1 (en) | 2017-08-29 | 2020-07-08 | Amgen Inc. | Macrocyclic compounds that inhibit mcl-1 protein |
US11332459B2 (en) | 2017-10-19 | 2022-05-17 | Teijin Pharma Limited | Benzimidazole derivatives and their uses |
MA54985A (fr) | 2018-03-05 | 2021-12-29 | Amgen Inc | Pharmacophores d'acide alpha-hydroxy phénylacétique ou antagonistes de la protéine bio-isostère mcl-1 |
WO2019222269A1 (en) | 2018-05-14 | 2019-11-21 | Reata Pharmaceuticals, Inc. | Biaryl amides with modified sugar groups for treatment of diseases associated with heat shock protein pathway |
KR102666717B1 (ko) | 2018-05-14 | 2024-05-20 | 길리애드 사이언시즈, 인코포레이티드 | Mcl-1 억제제 |
PE20211385A1 (es) | 2018-05-15 | 2021-07-27 | Lundbeck La Jolla Research Center Inc | Inhibidores de magl |
CN112739690A (zh) | 2018-07-24 | 2021-04-30 | 埃皮兹姆公司 | 用作smarca2拮抗剂的吡啶-2-酮化合物 |
AU2019374907A1 (en) | 2018-11-09 | 2021-06-03 | Prelude Therapeutics, Incorporated | Spiro-sulfonamide derivatives as inhibitors of Myeloid Cell Leukemia-1 (Mcl-1) protein |
US11498928B2 (en) | 2019-01-18 | 2022-11-15 | Ascentage Pharma (Suzhou) Co., Ltd. | Macrocyclic spiroethers as Mcl-1 inhibitors |
TWI778443B (zh) | 2019-11-12 | 2022-09-21 | 美商基利科學股份有限公司 | Mcl1抑制劑 |
AU2020391106B2 (en) | 2019-11-26 | 2024-03-21 | Gilead Sciences, Inc. | Processes and intermediates for preparing MCL1 inhibitors |
JP2021161114A (ja) | 2020-03-31 | 2021-10-11 | アムジエン・インコーポレーテツド | Mcl−1化合物のメチル化 |
TWI827924B (zh) | 2020-05-06 | 2024-01-01 | 美商安進公司 | 大環Mcl-1抑制劑中間體的閉環合成 |
BR112022022400A2 (pt) | 2020-05-06 | 2022-12-13 | Amgen Inc | Síntese de intermediários de álcool vinílico protegidos |
KR20230023008A (ko) | 2020-06-10 | 2023-02-16 | 얀센 파마슈티카 엔.브이. | Mcl-1의 억제제로서의 마크로사이클릭 2-아미노-3-플루오로-부트-3-엔아미드 |
CN115776888A (zh) | 2020-07-08 | 2023-03-10 | 詹森药业有限公司 | 含大环醚的吲哚衍生物作为mcl-1抑制剂 |
AU2021381769B2 (en) | 2020-11-19 | 2024-05-30 | Gilead Sciences, Inc. | Processes and intermediates for preparing macrocyclic mcl1 inhibitors |
-
2019
- 2019-05-13 KR KR1020237022152A patent/KR102666717B1/ko active IP Right Grant
- 2019-05-13 KR KR1020247015778A patent/KR20240074001A/ko active Search and Examination
- 2019-05-13 EP EP19728793.1A patent/EP3793565B1/en active Active
- 2019-05-13 SI SI201930181T patent/SI3793565T1/sl unknown
- 2019-05-13 ES ES19728793T patent/ES2907923T3/es active Active
- 2019-05-13 SG SG11202010964VA patent/SG11202010964VA/en unknown
- 2019-05-13 BR BR112020021648-8A patent/BR112020021648A2/pt unknown
- 2019-05-13 PT PT197287931T patent/PT3793565T/pt unknown
- 2019-05-13 LT LTEPPCT/US2019/032053T patent/LT3793565T/lt unknown
- 2019-05-13 PL PL19728793T patent/PL3793565T3/pl unknown
- 2019-05-13 DK DK19728793.1T patent/DK3793565T3/da active
- 2019-05-13 HU HUE19728793A patent/HUE057852T2/hu unknown
- 2019-05-13 MX MX2020012137A patent/MX2020012137A/es unknown
- 2019-05-13 UA UAA202006695A patent/UA125163C2/uk unknown
- 2019-05-13 US US16/410,457 patent/US10703733B2/en active Active
- 2019-05-13 EP EP21218221.6A patent/EP4029868A1/en active Pending
- 2019-05-13 IL IL291430A patent/IL291430B2/en unknown
- 2019-05-13 CA CA3099152A patent/CA3099152C/en active Active
- 2019-05-13 AU AU2019269391A patent/AU2019269391B2/en active Active
- 2019-05-13 KR KR1020207035485A patent/KR102551319B1/ko active IP Right Grant
- 2019-05-13 CN CN201980032695.2A patent/CN112118845B/zh active Active
- 2019-05-13 WO PCT/US2019/032053 patent/WO2019222112A1/en unknown
- 2019-05-13 PE PE2020001829A patent/PE20210004A1/es unknown
- 2019-05-13 HR HRP20220215TT patent/HRP20220215T1/hr unknown
- 2019-05-13 CR CR20200544A patent/CR20200544A/es unknown
- 2019-05-13 JP JP2020564228A patent/JP6899975B2/ja active Active
- 2019-05-13 CN CN202310897123.9A patent/CN117304130A/zh active Pending
- 2019-05-14 TW TW108116508A patent/TWI719478B/zh active
- 2019-05-14 TW TW110107128A patent/TWI813957B/zh active
-
2020
- 2020-04-23 US US16/857,021 patent/US10988451B2/en active Active
- 2020-10-27 IL IL278336A patent/IL278336B/en unknown
- 2020-11-03 PH PH12020551881A patent/PH12020551881A1/en unknown
- 2020-11-10 CL CL2020002919A patent/CL2020002919A1/es unknown
- 2020-11-10 CO CONC2020/0014009A patent/CO2020014009A2/es unknown
- 2020-11-10 ZA ZA2020/07007A patent/ZA202007007B/en unknown
-
2021
- 2021-02-09 US US17/171,201 patent/US11643400B2/en active Active
- 2021-03-09 JP JP2021037000A patent/JP7240431B2/ja active Active
- 2021-05-25 AU AU2021203373A patent/AU2021203373B2/en active Active
-
2022
- 2022-03-16 CY CY20221100208T patent/CY1125065T1/el unknown
-
2023
- 2023-03-03 JP JP2023032872A patent/JP2023060145A/ja active Pending
- 2023-03-09 US US18/181,336 patent/US20230312490A1/en active Pending
- 2023-11-24 AU AU2023270332A patent/AU2023270332A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1125065T1 (el) | Αναστολεις mcl-1 | |
CY1124891T1 (el) | Pd-1/pd-l1 αναστολεις | |
EA202091186A1 (ru) | ИНГИБИТОРЫ KRas G12C | |
CY1124730T1 (el) | Αντισωματα εναντι pd-1 και χρησεις αυτων | |
CL2021000084A1 (es) | Inhibidores de pd-1/pd-l1 | |
CY1120035T1 (el) | Πυριμιδοπυριμιδινονες χρησιμες ως αναστολεις της wee-1 κινασης | |
CY1124834T1 (el) | Αναστολεις της αλληλεπιδρασης της μηνινης-mll | |
CY1124613T1 (el) | Πυριμιδοπυριμιδινονες χρησιμες ως αναστολεις της wee-1 κινασης | |
AR121273A2 (es) | Inhibidores enzimáticos para uso en medicina y composición farmacéutica que los comprende | |
EA202092590A1 (ru) | Пиридазиноны в качестве ингибиторов parp7 | |
EA201992781A1 (ru) | Ингибиторы g12c kras и способы их применения | |
CY1121855T1 (el) | Παραγωγα βενζιμιδαζολιου ως αναστολεις βρωμοπεδιου | |
EA201792348A1 (ru) | Биарильные соединения, применяемые при лечении заболеваний человека в онкологии, нефрологии и иммунологии | |
EA201691421A1 (ru) | Гетероарилы и их применение | |
EA201690406A1 (ru) | Селективные ингибиторы grp94 и способы их применения | |
EA201692285A8 (ru) | Ингибиторы ezh2 для лечения лимфомы | |
CY1124123T1 (el) | Φαρμακευτικοι συνδυασμοι για θεραπεια καρκινου | |
CY1120751T1 (el) | Αναστολεις ετεροδικυκλοαρυλιου του rorc2 και μεθοδοι χρησης αυτων | |
CL2020003249A1 (es) | Antagonista gremlin-1 para la prevención y tratamiento del cáncer | |
CY1124655T1 (el) | Κρυσταλλικες μορφες και μορφες αλατος ενωσεων οι οποιες ειναι αγωνιστες του ppar | |
CL2021000650A1 (es) | Moduladores de la expresión de pnpla3 | |
BR112022008365A2 (pt) | Inibidores de cd73 | |
EA202192394A1 (ru) | Ингибиторы пути передачи сигнала notch и их применение для лечения рака | |
EA201790484A1 (ru) | Производные тетрагидрохинолина в качестве ингибиторов бромодомена | |
EA201890364A1 (ru) | СОЕДИНЕНИЯ, ПРИГОДНЫЕ ДЛЯ ИНГИБИРОВАНИЯ ROR-ГАММА-t |